|
|
|
|
 Roles for mitochondrial dysfunction in Alzheimer’s diseaseBenedict C. Albensi, Max Rady College of Medicine - University of Manitoba, Canada |
 Control of cellular bioenergetics by cytosolic calciumFranck Norbert Gellerich, Otto-von-Guericke University, Germany |
|
Alain Thierry, Montpellier Cancer Research Institute, INSERM, France |
|
|
 Down Syndrome: Role of hydrogen sulfide overproduction in the pathogenesis of mitochondrial dysfunctionCsaba Szabo, Université de Fribourg, Switzerland |
 Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosisDon Mahad, University of Edinburgh, United Kingdom |
|
Mitochondrial dysfunction in autism is distinct from mitochondrial disease
|
|
|
|
|
 Variety of non-coding RNA imported and encoded in mitochondriaEric Barrey, University Paris-Saclay, INRAE, AgroParisTech, France
|
Molecular mechanisms of ncRNAs transport into mitochondria: emerging approaches and potential gene therapy applications |
Long non-coding RNA SAMMSON and beyond: Uncoupling cytosolic and mitochondrial-translation as an effective anti-melanoma strategy |
Targeting long non-coding mitochondrial RNA for cancer therapy |
Round table: Prospective on other mitochondrial gene therapies |
 Mitochondrial disease community registry (MDCR): Perspectives from patients and families, lessons learned from the dataSophia Zilber, Boston, USA |
Welcome Note & Introduction Remarks
Mitochondria and microbiota dysfunction in COVID-19 pathogenesis
